Gene test could tailor chemo for tough pancreatic cancers
NCT ID NCT07592819
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to see if using a patient's genetic signature to choose chemotherapy can improve outcomes for people with borderline resectable pancreatic cancer. About 367 participants will receive standard chemotherapy, and researchers will track how long they live without major complications. The goal is to better understand which treatments work best for different genetic profiles.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS ADENOCARCINOMA (MSI-H) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI trained on thousands of pancreatic cancer cases could revolutionize diagnosis
- Exercise before and after pancreatic cancer surgery may speed recovery and chemotherapy start
- Light-Activated therapy targets pancreatic tumors during surgery
- Can your mood impact pancreatic cancer survival?
- Blood test may spot hidden pancreatic cancer after surgery
- New cocktail of drugs takes on tough pancreatic cancer